Severe Congenital Neutropenia 9 (SCN9): A Comprehensive Disease Characterization

Disease: Severe Congenital Neutropenia 9 (SCN9) MONDO ID: MONDO:0030726 · OMIM: 619813 · Gene: CLPB (SKD3; HGNC:30664) Category: Mendelian (autosomal dominant)

Summary

Severe Congenital Neutropenia 9 (SCN9) is a rare, autosomal-dominant inborn error of granulopoiesis caused by heterozygous, dominant-negative missense variants in CLPB (also called SKD3), a gene on chromosome 11q13.4 encoding a mitochondrial intermembrane-space (IMS) AAA+ ATPase that functions as a protein disaggregase/refoldase. The disease was formally delineated in 2021–2022 when two groups independently showed that monoallelic CLPB variants, clustering near the ATP-binding pocket, poison the wild-type CLPB oligomer and impair its disaggregase activity — a true dominant-negative mechanism rather than haploinsufficiency (PMID: 34115842; PMID: 34140661). This molecular lesion blocks granulocytic differentiation of hematopoietic progenitors and increases apoptosis of neutrophil precursors, producing a fully penetrant myeloid maturation arrest and severe neutropenia with recurrent bacterial infections beginning in infancy.

A central theme of this disease is its zygosity-dependent severity spectrum. The same gene, CLPB, causes two distinct Mendelian disorders: the monoallelic (dominant) form described here — SCN9 — which is typically isolated severe neutropenia; and a biallelic (recessive) form (OMIM 616271; 3-methylglutaconic aciduria type VII) that combines neutropenia with 3-methylglutaconic aciduria (3-MGA), cataracts, progressive brain atrophy, intellectual disability, movement disorder, epilepsy, and high early-childhood mortality. Critically, the metabolic hallmark 3-MGA-uria is characteristically absent in SCN9 (0/5 tested cases), and the monoallelic form carries a substantially better prognosis (4-year survival ~82% vs ~50% for biallelic disease).

Management parallels other severe congenital neutropenias: granulocyte colony-stimulating factor (G-CSF) maintains protective neutrophil counts and reduces infections, while allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option, reserved for G-CSF non-response or malignant (MDS/AML) transformation. Mechanistic work in cellular models points to ROS-driven apoptosis at the onset of differentiation, with experimental rescue by antioxidants (N-acetylcysteine), free fatty acids, or citrate — candidate future metabolic therapies. This report synthesizes 10 confirmed findings across 34 reviewed papers into a full, section-by-section disease knowledge base entry.

Key Findings

Finding 1 — SCN9 is caused by heterozygous dominant-negative CLPB variants (autosomal dominant)

SCN9 maps to MONDO:0030726 ("Neutropenia, severe congenital, 9, autosomal dominant"), cross-referenced to OMIM:619813, UMLS:C5676954, and GARD:0025625, with material basis in germline mutation in CLPB (HGNC:30664). The defining study, Warren et al. 2022 (Blood), used exome sequencing of 104 persons with congenital neutropenia to identify heterozygous missense CLPB variants in 5 severe congenital neutropenia cases, with 5 additional cases identified through supplementary sequencing — 10 total. The variants are not scattered but cluster near the adenosine-triphosphate–binding pocket of CLPB.

"Exome sequencing of 104 persons with congenital neutropenia identified heterozygous missense variants of CLPB (caseinolytic peptidase B) in 5 severe congenital neutropenia cases, with 5 more cases identified through additional sequencing efforts or clinical sequencing." — PMID: 34115842

"the CLPB variants are distinct, consisting of heterozygous variants that cluster near the adenosine triphosphate-binding pocket" — PMID: 34115842

This dominant form is molecularly and clinically distinct from the biallelic CLPB disease (OMIM 616271, 3-MGA-uria type VII, autosomal recessive).

Finding 2 — Mechanism: dominant-negative CLPB impairs mitochondrial disaggregase activity, blocking granulopoiesis and increasing apoptosis

CLPB (SKD3) is an AAA+ ATPase disaggregase/refoldase residing in the mitochondrial intermembrane space (IMS). SCN9 variants physically associate with wild-type CLPB and inhibit both its ATPase and disaggregase activities in a dominant-negative fashion. Both genetic loss of CLPB and expression of the variant protein impair granulocytic differentiation of human hematopoietic progenitors and increase apoptosis.

"These CLPB variants associate with wild-type CLPB and inhibit its adenosine triphosphatase and disaggregase activity in a dominant-negative fashion." — PMID: 34115842

"Both genetic loss of CLPB and expression of CLPB variants result in impaired granulocytic differentiation of human hematopoietic progenitor cells and increased apoptosis." — PMID: 34115842

A key mechanistic link is to HAX1, the protein mutated in SCN3 (Kostmann disease). CLPB maintains the solubility of HAX1, and HAX1 in turn acts as a direct stimulatory cofactor that oligomerizes and activates CLPB — tying two distinct neutropenia genes into one IMS proteostasis axis.

"loss of function in either gene causes severe congenital neutropenia as well as neuropathology and causes many proteins in the IMS and its bounding membranes to become insoluble" — PMID: 42244541

In CLPB-deficient myeloblasts, the downstream picture is reduced mitochondrial membrane potential, insoluble HAX1 aggregates, and ROS-driven apoptosis precisely at the onset of G-CSF-induced differentiation (PMID: 39644357). Monoallelic variants disturb refoldase activity (and to a lesser extent ATPase activity) dominant-negatively (PMID: 34140661).

Finding 3 — SCN9 phenotype is typically isolated severe neutropenia, lacking the neuro/metabolic features of biallelic disease

In Warren et al. 2022, heterozygous CLPB carriers had severe congenital neutropenia but — unlike biallelic disease — 3-methylglutaconic aciduria was not observed, and syndromic features (cataracts, neurological disease) were uncommon.

"3-methylglutaconic aciduria was not observed and, other than neutropenia, these clinical features were uncommon in our series" — PMID: 34115842

By contrast, the biallelic recessive syndrome (OMIM 616271) spans a neurological phenotype from nonprogressive intellectual disability to prenatal encephalopathy:

"a neurological phenotype ranging from nonprogressive intellectual disability to a prenatal encephalopathy with progressive brain atrophy, movement disorder, cataracts, and early death" — PMID: 25597510

A subset of monoallelic (de novo) cases do show some neurodevelopmental involvement (seizures, developmental delay), indicating a phenotypic spectrum rather than a clean dichotomy (PMID: 34140661).

Finding 4 — Zygosity predicts outcome: monoallelic disease is milder with better survival

Heath et al. 2026 assembled a cohort of 63 individuals (41 biallelic, 22 monoallelic) and quantified the zygosity-outcome relationship.

"Death occurred in 66% of biallelic and 23% of monoallelic individuals, with earlier median age at death in biallelic cases (6 months vs 2.4 years). Biallelic cases had significantly higher DBI scores and poorer survival (4-year survival: 50% vs 82%)." — PMID: 41719910

Notably, structural predictions (nonsense-mediated decay or ankyrin-repeat-domain disruption) were stronger predictors of survival than zygosity or age of onset alone, and stop/stop genotypes conferred greater disease burden than missense combinations. Early onset (<12 months) correlated with more severe progression.

Finding 5 — Treatment: G-CSF maintains counts and reduces infections; HSCT is definitive; antioxidant/metabolic rescue is experimental

In a CLPB-neutropenia case report, intermittent G-CSF successfully maintained protective neutrophil counts and cut respiratory infections:

"Administration of granulocyte colony-stimulating factor successfully maintained neutrophil counts above 0.5 × 109/L and significantly reduced the frequency of respiratory tract infections." — PMID: 41560087

Across congenital neutropenia syndromes, G-CSF responders retain residual risk of bone marrow failure, MDS, and AML (PMID: 38589208); HSCT is the only curative option for transformation or G-CSF non-response (PMID: 15640815; PMID: 15489867). Mechanistic rescue experiments identify candidate metabolic strategies:

"N-acetylcysteine, exogenous free fatty acids, or exogenous citrate protected CLPB-deficient 32Dcl3 cells from apoptosis at the onset of differentiation" — PMID: 39644357

Finding 6 — Model systems: zebrafish morphant, CLPB-KO 32Dcl3 myeloblasts, cross-species orthology

The zebrafish clpb morphant recapitulates the CNS phenotype of the recessive syndrome, with rescue specificity establishing variant pathogenicity:

"Suppression of clpb in zebrafish embryos induced a central nervous system phenotype that was consistent with cerebellar and cerebral atrophy that could be rescued by wild-type, but not mutant, human CLPB mRNA" — PMID: 25597510

The most neutropenia-relevant model is the CRISPR CLPB-knockout of the IL-3-dependent mouse 32D clone 3 (32Dcl3) myeloblastic line, which reproduces the differentiation/apoptosis defect:

"we used 32D clone 3 (32Dcl3) cells, an interleukin-3 (IL-3)-dependent mouse myeloblastic cell line model, to investigate the effects of CLPB knockout on myeloblast-to-neutrophil differentiation" — PMID: 39644357

Finding 7 — Inheritance & population genetics: AD via de novo dominant-negative missense; CLPB is LoF-tolerant

SCN9 arises through de novo monoallelic missense variants acting dominant-negatively:

"we identified one of four different de novo monoallelic missense variants in CLPB. We show that these variants disturb refoldase and to a lesser extent ATPase activity of CLPB in a dominant-negative manner" — PMID: 34140661

Critically, gnomAD constraint metrics exclude haploinsufficiency: pLI ≈ 2.4×10⁻⁵, observed/expected LoF = 40/78.4 (oe_lof 0.51, LOEUF 0.66), missense Z = 1.53 — i.e., heterozygous loss-of-function is tolerated. This confirms that disease requires a poison (dominant-negative) allele, not simple gene-dosage reduction. The biallelic form shows a Greenlandic founder cohort:

"Four of the individuals were of Greenlandic descent, and one was North American" — PMID: 25597511

Finding 8 — Diagnostics & anatomy: severe neonatal neutropenia with marrow maturation arrest; diagnosis by NGS/WES

Severe congenital neutropenia is defined hematologically by myeloid maturation arrest:

"characterized by a maturation arrest of myelopoiesis at the promyelocyte/myelocyte stage of development. This arrest results in severe neutropenia with absolute neutrophil counts (ANC) less than 0.2 x 10(9)/l associated with severe systemic bacterial infections from early infancy" — PMID: 10994541

Molecular diagnosis of CLPB-SCN relies on NGS gene panels / whole-exome or whole-genome sequencing; CLPB is now routinely included on congenital neutropenia panels (PMID: 40510848; PMID: 41383606), and reanalysis of previously negative exomes can reveal CLPB (PMID: 41560087).

Finding 9 — Downstream consequences & complications: IMS proteostasis collapse, infection susceptibility, MDS/AML risk

CLPB loss triggers stress-specific IMS protein aggregation that cripples mitochondrial quality control:

"CLPB deficiency impeding SPY complex function by virtue of protein aggregation in the intermembrane space" — PMID: 38270563

Clinically, the neutropenia drives recurrent severe bacterial infections, and like other SCN subtypes carries malignant transformation risk:

"neutropenia that can develop into leukemia" — PMID: 25597510

Finding 10 — Official HPO phenotype frequencies for SCN9

The HPO disease annotation for OMIM:619813 (source 34115842, n≈10) formalizes the phenotype frequencies, with the 0/5 for 3-MGA-uria confirming the metabolic hallmark of biallelic disease is absent in SCN9.

"3-methylglutaconic aciduria was not observed and, other than neutropenia, these clinical features were uncommon in our series" — PMID: 34115842

Full Section-by-Section Report

1. Disease Information

SCN9 is a rare Mendelian disorder of granulopoiesis producing severe, persistent neutropenia from early infancy, caused by heterozygous dominant-negative variants in CLPB. Key identifiers: MONDO:0030726, OMIM:619813, UMLS:C5676954, GARD:0025625. It falls under the broader ICD-10 category D70 (neutropenia) / ICD-11 4B00.0 (congenital neutropenia); MeSH maps to "Congenital Bone Marrow Failure Syndromes" / "Neutropenia." Synonyms/alternative names: Severe congenital neutropenia type 9; autosomal dominant CLPB-related neutropenia; CLPB-associated congenital neutropenia (monoallelic form). The information is derived primarily from aggregated disease-level resources (OMIM, Orphanet, HPO) and from small published case series/cohorts (Warren 2022, Wortmann 2021, Heath 2026) rather than from EHR.

2. Etiology

Primary cause — genetic: heterozygous (monoallelic) missense variants in CLPB/SKD3 that cluster near the ATP-binding pocket and act in a dominant-negative manner (PMID: 34115842; PMID: 34140661). Many arise de novo. Genetic risk factors: the causal variant is the sole established risk factor; no susceptibility loci or modifier genes are established for the dominant form, though structural impact (NMD vs ankyrin-domain disruption) modifies severity in the broader CLPB spectrum (PMID: 41719910). Environmental risk/protective factors: none identified — this is a monogenic disorder. Gene–environment interactions: none established; infection exposure determines clinical severity of complications but does not cause the disease.

3. Phenotypes

The core phenotype is a laboratory/hematologic abnormality — severe neutropenia (ANC often <0.2–0.5×10⁹/L) with bone-marrow myeloid maturation arrest (HP:0410253, 100%) — manifesting clinically as recurrent severe bacterial infections (HP:0002718) from early infancy. Onset is congenital/infantile (HP:0003593/HP:0003577). Severity is severe; course is chronic and lifelong but stabilizable with G-CSF. Non-hematologic features (cataract HP:0000518 20%; splenomegaly HP:0001744; seizure HP:0001250) occur at low frequency; 3-MGA-uria (HP:0003535) is characteristically absent (0/5). Quality-of-life impact: chronic infection susceptibility, repeated hospitalization, need for lifelong G-CSF injections and infection prophylaxis; well-managed patients can achieve good functional status, but transformation to MDS/AML is a severe QoL and survival threat.

4. Genetic / Molecular Information

Causal gene: CLPB (SKD3), HGNC:30664, OMIM gene 616254, Entrez 81570, Ensembl ENSG00000162129, UniProt Q9H078, locus 11q13.4 (GRCh38 chr11:72,285,495–72,434,680). Pathogenic variants: heterozygous missense variants near the ATP-binding pocket (dominant SCN9); biallelic missense/frameshift/nonsense (recessive 3-MGA-uria VII). Example recessive variants: c.1016delT (p.L339Rfs5), c.1087A>G (p.R363G) (PMID: 37906145); p.Arg408Gly abolishes ATPase function (PMID: 25597510). Classification: pathogenic/likely pathogenic per ACMG. Allele frequency: ultra-rare; gnomAD shows CLPB is LoF-tolerant (oe_lof 0.51, LOEUF 0.66), excluding haploinsufficiency. Origin: germline. Functional consequence: dominant-negative (SCN9) vs loss-of-function (recessive disease). Modifier genes: none validated; structural class of the variant is the main severity modifier. Epigenetic/chromosomal abnormalities:* none described.

5. Environmental Information

Not applicable as a cause — SCN9 is monogenic. Environmental triggers of complications include bacterial and viral pathogens (recurrent sepsis, respiratory/skin/oral infections; EBV reactivation has been reported in the CLPB/VPS45 neutropenia spectrum). No toxins, lifestyle, or occupational exposures contribute to disease causation.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. A heterozygous dominant-negative missense variant in CLPB (near the ATP-binding pocket) leads to a mutant CLPB subunit that is translated and imported into the mitochondrial IMS.
2. The mutant subunit co-assembles with wild-type CLPB into mixed oligomers and inhibits the complex's ATPase and disaggregase/refoldase activity (dominant-negative poisoning) — demonstrated biochemically (PMID: 34115842).
3. Loss of disaggregase activity results in failure to maintain solubility of IMS clients — notably HAX1 aggregation — and impairment of the proteolytic SPY complex (STOML2–PARL–YME1L1) (PMID: 42244541; PMID: 38270563).
4. IMS proteostasis collapse leads to reduced mitochondrial membrane potential and ROS accumulation in myeloid precursors (PMID: 39644357).
5. ROS/stress triggers apoptosis specifically at the onset of G-CSF–induced granulocytic differentiation, i.e., CLPB is a pro-survival factor at this checkpoint (PMID: 39644357).
6. Precursor apoptosis produces myeloid maturation arrest at the promyelocyte/myelocyte stage → severe peripheral neutropenia → recurrent bacterial infections from infancy.
7. Branch (downstream, inferred): chronic proliferative stress on the marrow contributes to clonal evolution and MDS/AML transformation risk, as in other SCN subtypes.

Molecular pathways: mitochondrial protein quality control / disaggregation; HAX1–CLPB axis; SPY proteolytic complex. Cellular processes: apoptosis (GO:0006915), response to ROS (GO:0000302), neutrophil differentiation (GO:0030223), protein refolding/disaggregation (GO:0042026). Protein dysfunction: dominant-negative impairment of an AAA+ ATPase disaggregase. Cell types: neutrophil (CL:0000775), promyelocyte (CL:0000836), granulocyte-monocyte progenitor (CL:0000557), hematopoietic stem cell (CL:0000037). Subcellular: mitochondrial intermembrane space (GO:0005758). CLPB assembles into homo-tetradecamers (apo) / homo-dodecamers (substrate-bound) with an essential N-terminal ankyrin-repeat domain (PMID: 36745679).

7. Anatomical Structures Affected

Organ level: bone marrow (UBERON:0002371) and blood (UBERON:0000178) are primary; spleen (splenomegaly in some) secondary. Body system: hematopoietic/immune. Cell level: neutrophils and their myeloid precursors (promyelocytes, GMPs, HSCs). Subcellular: mitochondria, specifically the intermembrane space (GO:0005758). Lateralization: not applicable (systemic hematologic disease). In the biallelic form, additional organs are involved — CNS (UBERON:0000955, brain atrophy), lens/eye (cataract), and ovary (premature ovarian insufficiency, PMID: 36074910).

8. Temporal Development

Onset: congenital/neonatal to infantile; neutropenia detectable from early infancy. Onset pattern: chronic from birth. Progression: generally stable neutropenia maintainable with G-CSF; risk of progression to marrow failure or MDS/AML over time. Early onset (<12 months) predicts more severe progression across the CLPB spectrum (PMID: 41719910). Course: chronic, lifelong. Remission: treatment-induced count normalization with G-CSF; no spontaneous cure. Critical period: the onset of granulocytic differentiation is the vulnerable checkpoint (where CLPB-dependent apoptosis occurs), and infancy is the window of greatest infection risk.

9. Inheritance and Population

Inheritance: autosomal dominant (SCN9, OMIM 619813), frequently de novo, dominant-negative (PMID: 34140661). Penetrance: myeloid maturation arrest appears fully penetrant (100%) in reported carriers; expressivity variable for non-hematologic features. Epidemiology: ultra-rare — dozens of families worldwide; the largest CLPB cohort assembled only 63 individuals across both zygosity forms (PMID: 41719910). Founder effects: a Greenlandic founder cohort exists for the biallelic form (PMID: 25597511); consanguinity enriches the recessive disease. Carrier frequency: not established (dominant form typically de novo). Sex ratio: both sexes affected, no strong skew. Age distribution: presents in infancy.

10. Diagnostics

Hematology: CBC showing severe neutropenia (ANC <0.2–0.5×10⁹/L); bone marrow aspirate showing promyelocyte/myelocyte maturation arrest (PMID: 10994541). Genetic testing (definitive): NGS congenital-neutropenia gene panels, WES, or WGS, now including CLPB; reanalysis of prior negative exomes is warranted (PMID: 40510848; PMID: 41383606; PMID: 41560087). Supportive discriminators: urine organic acids (3-MGA — normal in SCN9, elevated in biallelic disease; CHEBI:1890), slit-lamp exam (cataract), neuro-exam/MRI (recessive syndrome). Differential diagnosis: other SCN genes — ELANE (SCN1), GFI1 (SCN2), HAX1 (SCN3/Kostmann), G6PC3 (SCN4), VPS45 (SCN5), CSF3R (SCN7), SRP54 (SCN8), JAGN1, WAS — plus Shwachman-Diamond and cyclic neutropenia. Screening: no population newborn screening; cascade family genetic testing applies once a variant is known.

11. Outcome / Prognosis

Survival: monoallelic (SCN9) ~82% 4-year survival vs ~50% biallelic; death in 23% monoallelic vs 66% biallelic; median age at death 2.4 years (monoallelic) vs 6 months (biallelic) (PMID: 41719910). Morbidity: recurrent infections, hospitalizations; complications include sepsis, oral/periodontal and respiratory infections, hypersplenism, and MDS/AML transformation. Recovery potential: neutropenia is controllable (not curable) with G-CSF; HSCT can cure. Prognostic factors: zygosity, variant structural class (NMD/ankyrin-domain disruption > zygosity as predictor), age of onset (<12 months worse), disease burden index.

12. Treatment

Pharmacotherapy: G-CSF / filgrastim (NCIT:C1705-class) is first-line, maintaining ANC >0.5×10⁹/L and reducing infections (PMID: 41560087); pathogen-directed antibiotics (NCIT:C15847) for infections. Advanced therapeutics: allogeneic HSCT (NCIT:C15431) is the only curative option, indicated for G-CSF non-response, marrow failure, or MDS/AML (PMID: 15640815; PMID: 15489867). Experimental/metabolic: N-acetylcysteine (NCIT:C291), free fatty acids, or citrate rescued CLPB-deficient myeloblasts from apoptosis in vitro (PMID: 39644357) — candidate antioxidant/metabolic strategies not yet clinically validated. Supportive care: infection prophylaxis, prompt treatment of febrile episodes, dental/periodontal care. Pharmacogenomics / gene therapy / RNA therapy: none established.

13. Prevention

No primary prevention exists for this monogenic disease. Secondary prevention: early genetic diagnosis enabling prompt G-CSF and infection surveillance; routine monitoring for MDS/AML (serial CBC, marrow exams). Tertiary prevention: infection prophylaxis, timely HSCT before leukemic progression. Genetic counseling: autosomal dominant recurrence risk (often de novo); prenatal/preimplantation testing possible once the familial variant is known. Immunization/public health/environmental interventions: not applicable to disease causation (standard vaccination and infection control apply to the immunocompromised patient).

14. Other Species / Natural Disease

CLPB is evolutionarily conserved in the ClpB/Hsp100 AAA+ disaggregase family, with a bacterial ClpB homolog. Orthologs (NCBI Gene): mouse Clpb (GeneID 20480), rat Clpb (65041), zebrafish clpb (100331587); human CLPB Entrez 81570. No naturally occurring companion-animal or wildlife disease is documented (no OMIA entry noted). No zoonotic potential. The deep conservation of the disaggregase mechanism underpins the utility of zebrafish and rodent/cellular models.

15. Model Organisms

Zebrafish: morpholino clpb knockdown produces cerebellar/cerebral atrophy, rescued by wild-type but not mutant human CLPB mRNA — validating variant pathogenicity (PMID: 25597510). Cellular: CRISPR CLPB-knockout of IL-3-dependent mouse 32Dcl3 myeloblasts recapitulates the neutropenia-relevant defect — reduced mitochondrial membrane potential, insoluble HAX1 aggregates, ROS-driven apoptosis at G-CSF-induced differentiation (PMID: 39644357). Biochemical reconstitution: purified human CLPB + HAX1 systems (PMID: 42244541) and cryo-EM structural models (PMID: 36745679). Phenotype recapitulation: zebrafish captures the neurological (recessive) phenotype; 32Dcl3 captures the myeloid differentiation defect. Limitations: no dedicated mouse model of the dominant SCN9 phenotype is yet reported; morphant models have known off-target caveats.

Mechanistic Model / Interpretation

 Heterozygous dominant-negative CLPB missense variant (near ATP-binding pocket)
                         │
                         ▼
   Mutant subunit co-assembles with WT CLPB in mitochondrial IMS
                         │  (dominant-negative poisoning — demonstrated)
                         ▼
     ↓ CLPB ATPase & disaggregase/refoldase activity
                         │
            ┌────────────┴─────────────┐
            ▼                          ▼
   HAX1 aggregation          Impaired SPY complex
   (insoluble IMS clients)   (STOML2–PARL–YME1L1)
            └────────────┬─────────────┘
                         ▼
     ↓ mitochondrial membrane potential → ROS accumulation
                         │
                         ▼
   Apoptosis at ONSET of G-CSF-induced granulocytic differentiation
                         │
                         ▼
   Myeloid maturation arrest (promyelocyte/myelocyte)  ──► SEVERE NEUTROPENIA
                         │                                        │
                         ▼                                        ▼
         Recurrent bacterial infections (infancy)        MDS/AML risk (downstream, inferred)

Zygosity–mechanism–outcome synthesis:

The unifying insight is that CLPB sits at the heart of a mitochondrial IMS proteostasis network linking it to HAX1 (SCN3/Kostmann) — explaining why two genetically distinct congenital neutropenias converge on the same disaggregase pathway. gnomAD LoF-tolerance proves that one functional allele suffices for neutrophil production; disease in SCN9 therefore requires an actively interfering allele, and the poisoned oligomer tips neutrophil precursors into ROS-driven apoptosis at their most vulnerable differentiation checkpoint.

Evidence Base

Limitations and Knowledge Gaps

1. Very small sample sizes. The disease rests on ~10 heterozygous cases (Warren 2022) and a combined cohort of 63 across both zygosity forms (Heath 2026). HPO frequencies (e.g., cataract 2/10) have wide confidence intervals.
2. No dedicated dominant-model organism. Mechanistic data derive from CLPB-knockout cell lines and morphant zebrafish that model loss of function/recessive phenotypes, not the dominant-negative SCN9 state specifically.
3. Spectrum vs dichotomy. Some monoallelic cases show neurodevelopmental features, blurring the clean "isolated neutropenia" picture; genotype–phenotype rules remain incompletely defined.
4. No validated epidemiologic prevalence/incidence for SCN9 specifically (ultra-rare; registry data limited).
5. Metabolic/antioxidant rescue is in vitro only — NAC, FFA, and citrate have not been tested clinically.
6. Leukemic transformation risk is extrapolated from SCN broadly; CLPB-specific transformation rates are not quantified.

Proposed Follow-up Experiments / Actions

1. Generate a knock-in mouse carrying a human SCN9 dominant-negative CLPB missense allele to establish an in-vivo dominant model and quantify neutrophil, survival, and MDS/AML outcomes.
2. Prospective natural-history registry for CLPB-neutropenia to firm up prevalence, penetrance, transformation rates, and genotype–phenotype correlations (expanding the Heath 2026 cohort).
3. Preclinical trial of antioxidant/metabolic rescue (N-acetylcysteine, citrate, free fatty acids) in CLPB-deficient primary human CD34⁺ progenitors and the knock-in mouse, moving toward a pilot clinical study.
4. Structural/biochemical dissection of how each variant class (ATP-pocket missense vs ankyrin-domain disruption) poisons the oligomer, to build a variant-to-severity predictor usable in counseling.
5. Longitudinal MDS/AML surveillance protocol specific to CLPB-SCN, correlating clonal markers (e.g., CSF3R/RUNX1 mutations) with transformation.
6. Systematic HAX1–CLPB interaction mapping in patient-derived cells to test whether HAX1 stabilization can bypass the CLPB defect therapeutically.

Evidence source types represented: human clinical (cohorts/case reports), model organism (zebrafish), in vitro (32Dcl3 knockout, biochemical reconstitution, cryo-EM), and computational (gnomAD constraint, structural prediction).